TICKERNERD
Menu
PFEPFEHealthcare · Drug Manufacturers - General

PFE Stock Forecast: Pfizer Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$28
+0.25% on the day

The 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $28 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$158.0B
Ticker Nerd rank
78 / 100
Median analyst target
$28
Analysts covering
28
Revenue$15.0B+2.6% y/y
Operating income$3.5B
Net income−$237.0M
Free cash flow$302.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
+4.1%
YTD
+17.0%
1Y
+19.2%
From 52W high
−4.5%
From 52W low
+25.6%
$22
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PFE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Value
97
Quality
92
Accruals
76
Momentum
69
Revisions
61
Issuance
51
Growth
38
Size
2

Volatility (97): The share price has been relatively steady.

Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PFE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Oct 25Jan 26Apr 26Jul 26PFEHigh $36Median $28Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
10 Buy16 Hold2 Sell
Low $25Median $28High $36

The green dot is the last close — the median target sits +1.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsHold$28 → $30
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$35 → $31
13 July 2026BMO CapitalMaintainsOutperform—
13 July 2026BMO CapitalMaintainsOutperform$34 → $30
13 July 2026GuggenheimMaintainsBuy$36 → $35
13 July 2026GuggenheimMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsNeutral$27 → $26
10 July 2026B of A SecuritiesMaintainsNeutral—
8 July 2026JP MorganMaintainsNeutral—
8 July 2026JP MorganMaintainsNeutral$30 → $28
6 July 2026Cantor FitzgeraldReiteratesNeutral$27
6 July 2026Cantor FitzgeraldReiteratesNeutral—
6 July 2026HSBCDowngradeHold$32 → $28
6 July 2026HSBCDowngradeHold—
10 June 2026RBC CapitalUpgradeSector Perform—
29 Apr 2026CitigroupMaintainsNeutral—
20 Apr 2026RBC CapitalReiteratesUnderperform—
16 Apr 2026CICCInitiatesOutperform—
13 Apr 2026UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PFE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Pfizer Inc. returned +19.2% against +17.5% for the S&P 500, dividends included.

PFE vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26PFES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PFE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.5%
Analysts raising
15
Analysts cutting
4
Fundamentals

Pfizer Inc. (PFE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.5×

Cheaper than 21% of US stocks

Price / sales
2.5×

Cheaper than 47% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
8.3×

Cheaper than 44% of US stocks

Growth & margins
Revenue growth (YoY)
2.6%

Higher than 33% of US stocks

Earnings growth (YoY)
2.6%

Higher than 39% of US stocks

Gross margin
72.8%

Higher than 85% of US stocks

Operating margin
27.9%

Higher than 86% of US stocks

Net margin
6.8%

Higher than 64% of US stocks

Returns & dividend
Return on equity
5.0%

Higher than 53% of US stocks

Return on assets
5.8%

Higher than 80% of US stocks

Dividend yield
6.2%

Higher than 86% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pfizer Inc. (PFE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pfizer Inc. has a market value of $158.0B and an enterprise value of $210.1B.

  • Revenue in the twelve months to 30 June 2026: $63.7B. The latest quarter grew 2.6% year on year.

  • Net income over the same four quarters: $4.4B, a 6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.76.

  • Free cash flow in the twelve months to 30 June 2026: $11.0B.

  • Pfizer Inc. spent $9.8B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 5.7B.

  • Trailing P/E: 36.5×; forward P/E: 9.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 6.21%, paying out 226% of earnings.

  • Pfizer Inc. employs 75,000 people — $849K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PFE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
PFEPfizer Inc.$158.0B
78
GILDGilead Sciences, Inc.$178.4B
93
BMYBristol Myers Squibb Co.$129.6B
99
AMGNAmgen, Inc.$203.4B
90
MRKMerck & Co., Inc.$357.2B
82
ABBVAbbVie, Inc.$454.3B
96
JNJJohnson & Johnson$640.0B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PFE news & analysis

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

WSJ · 13 Sept 2026negative

Pfizer has targeted air-traffic control fees in a $2 billion dispute with Poland and Romania over unwanted Covid-19 vaccines, an unusual legal tactic in a fight reportedly involving the drugmaker versus the two European governments.

Why it matters — A PFE watcher would care because this dispute highlights ongoing complications and legal exposure related to Covid-19 vaccine supply agreements with European governments.

How Concerned Should Income Investors Be About Pfizer's Dividend?

The Motley Fool · 12 Sept 2026neutral

The Motley Fool examines Pfizer's dividend, noting the company offers a well-above-market yield while facing typical industry headwinds that make the dividend appear risky to income investors.

Why it matters — PFE watchers will care because the article assesses the sustainability of Pfizer's dividend amid industry pressures, which is a key concern for income-focused shareholders.

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Proactive Investors · 12 Sept 2026neutral

Medicus Pharma CEO Raza Bokhari detailed progress on its SkinJect program and a co-development and licensing opportunity with Pfizer, noting that final SkinJect results published on ClinicalTrials.gov confirmed the 200-microgram patch as the dose to move into further registrational studies. Bokhari highlighted clinical, partnership and funding developments as the company focuses on precision oncology and capital-efficient drug development.

Why it matters — A PFE watcher would care because the news signals Medicus Pharma's clinical and funding progress around a co-development and licensing opportunity involving Pfizer.

Here are the stocks to favor in the fourth quarter — and those you should avoid

Market Watch · 10 Sept 2026neutral

Market Watch reported that large-cap stocks tend to outperform small caps as the fourth quarter approaches, offering general guidance on stock preferences for the end of the year. The article does not specifically mention Pfizer or any individual company.

Why it matters — As a large-cap company, Pfizer could be positioned within the type of stocks the article suggests tend to do well as year's end approaches, though the report contains no company-specific information.

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

MarketBeat · 10 Sept 2026neutral

Novavax executives outlined a pivot from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, highlighting near-term catalysts around Sanofi's commercial rollout of NUVAXOVID, combination vaccine development, and early oncology research.

Why it matters — Pfizer watchers would note Novavax's shift toward partnership-driven growth, which centers on its Matrix-M adjuvant and includes potential catalysts tied to Pfizer's collaboration.

FAQ

Frequently asked questions about PFE stock

What is the PFE stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $28, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PFE stock a buy right now?

Of the 28 analysts covering Pfizer Inc., 10 rate it a Buy, 16 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 78 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PFE?

As at 12 Sept 2026, Pfizer Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will PFE stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 78 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PFE stock forecast for 2030?

No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.

How has PFE stock performed over the past year?

Pfizer Inc. returned +19.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pfizer Inc. do?

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide.

What is the latest news on PFE?

The most recent item we track (WSJ, 13 Sept 2026): "Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines". Pfizer has targeted air-traffic control fees in a $2 billion dispute with Poland and Romania over unwanted Covid-19 vaccines, an unusual legal tactic in a fight reportedly involving the drugmaker versus the two European governments.

Company

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets. The company plays a central role in global healthcare by supplying prescription therapies and immunizations across major therapeutic areas, while its research and development organization continues to support the launch, approval, and lifecycle management of new treatments. Founded in 1849 and headquartered in New York City, Pfizer Inc. remains one of the most recognized names in the pharmaceutical industry.

CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com